Eliminating residual iPS cells for safety in clinical application

First-in-human clinical trial for age-related macular degen- eration using iPSC-derived retinal pigment epithelium （RPE） cells was conducted in 2014, showing no serious adverse effects to date, including tumor formation. This appears to be attributable to relatively small number of transplanted cells, and distinct morphology of RPE cells; it might be relatively easy to minimize contamination of undifferentiated cells. However,